Fulgent Genetics, Inc. is a leading provider of clinical diagnostic and therapeutic development solutions for patients and physicians around the globe. The company boasts an impressive portfolio of clinical diagnostic solutions, including molecular and genetic testing, as well as anatomic pathology laboratory tests and oncology testing services. Additionally, the company offers next generation sequencer services related to key areas such as cardiovascular genetics and pharmacogenetics. Fulgent Genetics, Inc.'s therapeutic development solutions are focused on utilizing innovative nanoencapsulation and targeted therapy platforms to create promising drug candidates for treating a range of cancers. These drug candidates are designed to enhance the therapeutic window and pharmacokinetic profile of new and existing cancer treatments. The company also operates the picture genetics platform, which leverages proprietary gene probes, data suppression and comparison algorithms, adaptive learning software, and laboratory information management systems to help customers identify health markers in their personal DNA. Fulgent Genetics, Inc. serves a wide range of clients, including insurance providers, medical institutions, government bodies, payors, and patients. The company was founded in 2011 as Fulgent Diagnostics, Inc. and changed its name to Fulgent Genetics, Inc. in August 2016. Its headquarters are located in Temple City, California.
Fulgent Genetics's ticker is FLGT
The company's shares trade on the NASDAQ stock exchange
They are based in Temple City, California
There are 51-200 employees working at Fulgent Genetics
It is ir.fulgentgenetics.com
Fulgent Genetics is in the Healthcare sector
Fulgent Genetics is in the Diagnostic Substances industry
The following five companies are Fulgent Genetics's industry peers: